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Other vaccines include polypeptides containing specific
HBV-antigenic determinants. Clinical trials of polypeptide
vaccines are in progress. Hybrid virus vaccines for HBV
utilising recombinant vaccinia viruses have been developed.
These vaccines have certain theoretical advantages in that a
single strain of vaccinia may be designed to present
antigens characteristic of several viral diseases
simultaneously. However, at present, the use of vaccinia
virus remains experimental. Other recombinant viruses being
investigated as vectors for hepatitis vaccines include
adenoviruses and polioviruses, which may be effective when
given by mouth.
The potential for the generation of vaccine-induced
escape mutants in neonates born to HBV-infected mothers
exists" but may be preventable by alterations in the
recombinant vaccines.
Conclusion
A major concern in southern Africa is to control hepatitis B
virus infection and thus prevent the appalling sequelae of
chronic infection. Universal vaccination of infants in high-risk
areas in South'Africa will be an important step in the
reduction of liver disease in our country.
The introduction of a national hepatitis B vaccination
programme in South Africa is imminent. This policy must be
supported by the political will to control HBV infection. This
entails the provision of adequate resources for vaccination
and surveillance, as well as general public health measures
aimed at preventing transmission.
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Hepatitis C - a South
African perspective
Michael D. Voigt, Heidi Smuts
The existence of non-A, non-B (NANB) hepatitis was
established in the 1970s, when accurate serological tests
allowed exclusion of hepatitis A and B viruses as the cause
of most cases of post-transfusion hepatitis.' The term
'hepatitis C' was coined after molecular cloning of nucleic
acid from highly infectious sera of chimpanzees2 identified
an RNA virus as the primary cause of post-transfusion
hepatitis (PTH). Sequence analysis and expression of the
RNA has shown it to be closely related to the flavi- and
pestiviruses. It has marked genomic variability which may
affect its biological and immunological characteristics, is
transmitted parenterally and sporadically, by as yet
unidentified routes, and causes chronic indolent liver
disease in 50 - 75% of infected patients. It is associated
with hepatocellular carcinoma, glomerulonephritis,
cryoglobulinaemia, auto-immune liver disease, lymphocytic
sialadenitis and porphyria cutanea tarda. Up to 500 million
people worldwide may be infected with hepatitis C virus
(HCV),3 and many questions about the disease remain
unanswered. Therapy is still largely ineffective and our
current understanding of the long-term natural history, our
methods of diagnosis, therapy, prevention and immunisation
are suboptimal.
Virology of HeV
HCV was first obtained by screening the products of
approximately 1 million c-DNA clones expressed in
bacteriophage vectors, with serum from patients with
NANB PTH! The sequence of the first clone identified
(5-1-1) encoded a 55 amino acid peptide containing an
MRC/UCT Liver Research Centre, Departments of Medicine and
Microbiology, University of Cape Town
Michael D. Voigt, M.B. CH.B., F.C.!' (SA), M.MED. (MED.)
Heidi Smuts, PH.O
-
SAMJ IfoIlIIlle 84 'a. 8 August 1994
Table J. Comparison of three HCV classifications
Genotypes may differ in their geographic distribution,
virulence and in the levels of viraemia they produce, in their
cell tropism, transmissibility and responsiveness to therapy
with interferon. Genotypes 1 and 2 (Simmonds'
nomenclature) are globally distributed, while others: are more
restricted {type 3 Europe; type 4 Middle East and Egypt;
type 5 South Africa; type 6 Hong Kong).'6,'S.22.23.25-27
The sequence coding for amino acids 384-414 is
hypervariable, with mutations occurring at a high rate from
infection to infection and over time in individual patients.
The variable regions may play a role in protection against
immune surveillance and hence persistence of infection.'s.3o
In contrast the 5' untranslated region and N-terminal C
(core) protein have highly conserved domains which are
similar in all genotypes and, indeed, in the pestiviruses,3'
which suggests that these conserved domains perform
crucial biological functions. Models of the 5' untranslated
region have shown it to have a complete stem-loop
structure,"·3' with mUltiple functions."
Different HCV genotypes may be associated with
variations in the severity of clinical and histological
disease, and its responsiveness to interferon therapy.'027.32
Patients infected with type 1 HCV appear to have more
severe hepatitis, a greater risk of developing cirrhosis and a
poorer response to interferon therapy.",32 Increased disease
severity may be a specific feature of the type 1 genotype, as
no correlation of disease severity with the other genotypes
was found in two large series,27,33 but results have been
conflicting.34 Several studies have shown a correlation
between viral genotype and interferon responsiveness.27,34-36
Type 1 infections appeared to respond relatively poorly27
while type 2 infections responded better to therapy.35
Levels of viraemia, which may be affected by the genotype,
could influence the response to therapy.27.33,35 It is unclear
whether infection with several different strain of HCV
affects responsiveness to' therapy. Hino et al. 36 found that
infection with multiple genotypes of HCV did not affect
responsiveness to interferon therapy, although Okada et al. 37
have suggested that multiple infections may aid escape from
immune responses. The number of mutations increases with
time, and patients with long-standing infections could
therefore have a poorer response to therapy as a result.
Patients can be simultaneously infected with more than one
genotype; flares of activity occur with each new infection,
indicating the lack of cross-protective antibodies between
different genotypes.38
immunodominant epitope that reacted strongly with sera
from NANB but not hepatitis A- or hepatitis B-infected
patients. Hybridisation with and sequencing of overlapping
clones allowed full identification of the original HCV isolate
genome as a positive-sense RNA of 9 401 ribonucleotides.
The genome contained a 5' untranslated region of 341
bases, a large open reading frame of 9 033 bases encoding
a polyprotein of 3 011 amino acids and a 27-base poly-A tail
at the 3'-end.
It has now been confirmed that the hepatitis C agent is an
enveloped virus of approximately 50 nm with a positive-
sense RNA genome of roughly 9 500 nucleotides with a
single, long, open reading frame. The HCV resembles the
flaviviruses and pestiviruses' but is sufficiently different from
them to be placed in its own genus' Replicating virus uses
a minus-strand RNA intermediate template. Detection of this
minus strand may therefore indicate that active HCV
replication is taking place in the tissue.s Genomic RNA is
probably translated into a single polyprotein of
approximately 3 011 amino acids, which is then processed
into functional proteins.' The putative structure and function
of these proteins has been ascertained by analysis of the
amino acid sequence predicted from the ribonucleic acid
sequence, by analysis of expressed recombinant proteins
and analogies drawn from prior knowledge of the closely
related flavi- and pestiviruses. The putative structural
proteins, namely the single nucleocapsid and two envelope
proteins, are located at the amino terminal end of the
polyprotein and are derived from the 5' third of the genome.7
The two envelope proteins (gp33 and gp72) are thought to
be glycosylated products derived from expression of the E1
and E2 regions of the genome respectively. Variable and
hypervariable regions in the envelope glycoproteins have
been described,"· and may play a role in escape from host
immunity. Downstream from the structural proteins are the
non-structural (NS) proteins which are the products of the 3'
two-thirds of the genome (NS1-NS5 region). They have
protease, helicase and replicase domains which may be
involved in RNA replication and protein processing.' The 5'
untranslated end is highly conserved in different HCV strains
from around the world (Fig. 1).'0.11
Electron microscopic demonstration of putative HCV




HCV may be classified into a number of distinct but related
genotypes by sequence differences of both the coding and
non-coding regions of the genome,"·13.'. or into serotypes,
by identification of antibodies which react with synthetic
peptides from different genotypes.'" Many different
nomenclatures are currently in use to describe the
genotypes, and this has resulted in difficulty in comparing
results. Classifications described by Houghton et al., 2'
Cha et al., '8 Simmonds et al.,23 Okamoto et al. 24.25 and
Enomoto et al. ,. are widely used. These classifications are
compared in Table I.
Chan et al. 22



























Because hepatitis C viral antigens are present in very low
concentrations, they are undetectable by conventional
assays. The presence of HCV infection is ascertained either
by detection of antibody to the virus or by detection of HCV
RNA in serum or tissue.
First-generation C100-3 (NS4) assay
The first-generation tests used the C100-3 recombinant
peptide derived from the non-structural NS4 region. It
represented approximately 4% of the total genome and as a
result there was a significant false negative rate, and
numerous patients with HCV were missed with this assay.39-41
This resulted in ongoing PTH from donors screened
negative.
Second-generation assays
Second-generation assays incorporate recombinant
antigens and/or synthetic peptides derived from NS3, NS4
and core regions (Fig. 1). Solid-phase enzyme-linked
immunosorbent assays (ELlSAs) based on the C33, C200
and C22 antigens, derived from these non-structural NS3,
NS4 and core regions and expressed in Escherichia coli or
yeast, form the basis of the Ortho (New Jersey) and Abbott
(Chicago) second-generation assays. These assays have
improved sensitivity and specificity."
immunodominant epitope of the HCV capsid region
comprising amino acids 31 - 45....... Assays based on this
domain of the core protein, are highly specific « 6% false-
positive rate) and sensitive (68% correlation with PCR and
97% with antibody tests to the envelope plus NS3/4 regions)
in identifying chronic HCV infection."" Antinucleocapsid
antibodies appear early in the course of infection; these may
therefore be more sensitive in early detection of acute HCV
hepatitis!' Because anti-core titres fall with resolution of
hepatitis but rise with active disease, they may be useful in
assessing the intensity of HCV activity." However, antibodies
to core are probably not neutralising, as they have been
detected in chronically infected subjects. In contrast,
antibodies to (E) envelope glycoproteins may be neutralising
in some, but not all, cases.48
IgM-based assays
Although not commercially available, IgM-based assays
have been developed in an attempt to distinguish acute from
chronic HCV infection. In acute infections, IgM antibodies to
the core protein are detected early in the course of the
disease and persist for approximately 8 weeks!9
Unfortunately, IgM responses do not always follow a classic
course, and may appear later than IgG antibodiesso or
remain positive in chronic HCV infections.51 The persistence
of IgM anti-core antibodies in chronic infection appears to
indicate active infection as they correlate with the presence
of HCV RNA.50.52 IgM anti-core antibodies may be a good
indicator for a positive response to interferon therapy.51.53.",
Antibody to HCV structural proteins
(nucleocapsid and envelope)
A chimeric polyprotein called C25, comprising fused
immunodominant regions of the nucleocapsid (C) and the
non-structural NS4 and NS5 regions, has significantly
improved the sensitivity and specificity for detection of both
acute and chronic HCV infections.43 Accuracy of HCV assays
has been further improved by the identification of a small
Supplemental (confirmatory) assays
False-positive results may occur because of detection of
passively acquire':J HCV antibodies in transfusion recipients,
cross-reactivity with vector or fusion proteins and in
association with auto-immune diseases (vide infra).55." In
addition, positive antibody tests do not distinguish between
resolved and chronic infections. Tt:Jese problems are
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Fig. 1. Second-generation assays incorporate recombinant antigens and/or synthetic peptides derived from NS3, NS4 and core regions.
-
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disease increases the number of false-positive cases,
according to Bayes theorem. Supplemental and
confirmatory assays, e.g. neutralisation, recombinant
immunoblot assay (RIBA) and Western blot, have therefore
been developed to improve diagnostic accuracy for HCV
infection. 57 RIBA detects antibodies to antigens which are
coated in separate bands on a nitrocellulose strip. The
RIBA-2 tests for 2 antigens, 1 structural (C-22) and 1 non-
structural (C33c), and positive results were found to
correlated with the presence of HCV RNA58.59 The RIBA-4
detects 4 antigens (C100-3, 5-1-1, C33c, C22). Reactivity
with 2 or more antigens indicates a high probability (> 90%)
of true HCV infection. A strong correlation exists between
positive RIBA-4 and viraemia, allowing discrimination
between infective and non-infective sera53.60 However, sera
with antibodies reactive only with C100-3 and 5-1-1
antigens from the NS4 region are often not associated with
HCV RNA"' as these may persist after the virus has been
cleared. Sera reactive to a single C22 or C33 recombinant
product have a low probability of containing HCV RNA52
Cell-mediated immunity
Cell-mediated immunity appears to be important in host
responses to the disease. Proliferative responses of CD4+
T cells to recombinant HCV synthetic core protein correlate
with a benign course of the disease in subjects infected with
the virus.53
HCV-RNA detection
Because HCV RNA circulates in low concentrations,
sensitive detecting assays have been developed. Average
plasma concentrations of virions vary from 102to 5 x 10'
virions/m!.64 The reverse-transcription polymerase chain
reaction (RT-PCR) for the detection of HCV RNA is the most
sensitive marker of viraemia and infectivity. Specific
oligonucleotide primers are used in single or nested PCR
systems·5.•' and have a sensitivity which potentially allows
for the detection of single molecules. Due to sequence
variability of different HCV isolates, highly conserved regions
of the genome especially the 5' NCR are targeted. This
allows for the detection of RNA from all strains of HCV."'9
Specificity and sensitivity of detection may be enhanced by
means of a nested system,'o." and the need to probe may
be obviated by use of labelled primers in nested systems.'O.72
PCR remains largely a research technique as it is time-
consuming, requires relatively sophisticated equipment, and
standardisation and quality control are difficult. However, a
commercial HCV RNA detection kit (HCV Amplicor; Roche
Diagnostics) is available. Chiron have also introduced an
HCV RNA assay that uses branched DNA amplification in
which the detection system rather than the target
sequence"·73 is amplified (i.e. signal amplification). Although
not as sensitive as PCR (detection limit 350 000 equivalents
per ml), it may be used as a quantitative assay. Semi-
quantitative competitive RT-PCR assays have also been
described.3o.74 Measurement of HCV RNA levels is useful in
correlating severity of disease and antiviral therapy. Lau
et al. '3 have shown that patients with low HCV RNA serum
levels respond better to interferon therapy than those with
high RNA levels. The level of viraemia may also correlate
with HIV co-infection, the mode of transmission, and with
histological scores. High HCV RNA levels are associated
with increased lobular inflammation, lymphoid aggregates
and bile duct abnormalities.'3
The PCR te~hnique is highly sensitive, differentiates
resolved from active infection in patients with antibodies,"
allows identification of HCV infection early in the acute phase
before the appearance of antibodies,'··77 is useful in
monitoring the effect of interferon or other antiviral therapies'·
and, by detecting minus strand RNA viral intermediates, is
able to identify sites of active HCV replication.' Result~ of
PCR should, however, be regarded with caution until
techniques have improved.'9 When 31 laboratories tested a
coded panel of serum samples, only 5 (16%) of these
laboratories performed faultlessly on all samples. Both false
positive and false negative results were common in this
study, which included many leading research and academic
laboratories. Apart from poor technique, other causes of
incorrect results need to be considered:
1. False-positive results may occur as a result of
amplicon contamination. Great care must be taken to
separate pre- and post-PCR procedures; the guidelines of
Kwok and Higushi60 should be followed.
2. False-negative results can occur if inhibitors of the RT-
PCR reactions are present in the RNA sample. An internal
control for a single copy gene, e.g. actin or ~-globin, should
be included to identify this problem. Inadequately stored sera
or those subjected to multiple freeze/thaw cycles may give
false-negative results because of the degradation of the RNA
Transmission
Hepatitis C circulates in low titres and is most efficiently
transmitted by parenteral routes, especially by blood and
blood products, shared intravenous (IV) drug needles,
accidental needle-stick injuries·' and via transplanted
organs·2.•9However, fewer than half of HCV-infected
patients have had parenteral exposure to the virus.
Community-acquired HCV is sporadic, transmitted mostly by
unknown routes, but possibly also by sexual transmission,
from mother to infant or via saliva. There is increasing
evidence that transmissibility is increased when circulating
HCV RNA titres are high.
Sexual transmission
Although sexual partners of HCV-positive haemophiliacs,
and IV drug users, both homosexual90 and heterosexual,
have higher rates of HCV infection than the general
population, especially when the latter are simultaneously
HIV-positive,9' this may reflect the effect of confounding risk
factors and not sexual transmission per se. Osmond et al. 92
showed that HCV infection correlated with injection drug
use, haemophilia and blood transfusion but not with sexual
behaviour, number of sexual partners, history of sexually
transmitted disease or HIV disease92 Similarly multivariate
analysis has failed to show a significant sexual transmission
of HCV in the sexual partners of high-risk individuals when
other confounding risk factors were considered.93 Multiple
sexual partners in the previous 3 months and receptive anal
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intercourse were thus associated with positivity to hepatitis
B core antigen but not to anti-HCV.93 In addition, HCV has
not been found in semen samples."' However, up to 45% of
commercial sex workers in some areas are HCV positive95
although studies from other areas have identified antibodies
in only 3,5% of this group. Higher prevalences may be due
to simultaneous IV drug use or other risk factors, However,
of 37 female partners of HCV-positive men, who had had no
parenteral exposure or risk factors for HCV, 2 had HCV
infection suggesting low-grade sexual transmission." It is
not clear whether HCV may be transmitted by kissing, but
HCV is present in the saliva of affected subjects97,.. and
transmission by human bite has been reported.99
Intrafamilial transmission
Intrafamilial spread is uncommon,'Oll but has been
reported '01 ,l02 and may be more common if the index patient
has a high viral load.'o, Up to 8% of Japanese family
members of index patients may be HCV positive; this
suggests that transmission may be more common in certain
areas.'03
Vertical and perinatal transmission
Infants born to HCV-seropositive mothers with no HIV co-
infection have a low but significant risk of between 0%'0-<
and 10%'05,'06 of developing HCV infection. The risk in HCV
RNA-positive mothers appears to be greater, if the mothers'
HCV RNA titre is high. Ohto et al. '07 showed that if this titre
exceeds 106virions/ml the risk of transmission of HCV to
infants is 36%, whereas if the titre was below 106or when
HCV RNA was negative, there was no transmission to the
infant. Nucleotide sequencing of viruses from mothers and
infants showed 97 - 99% homology, compared to homology
of 66 - 92% between infants. This confirms that vertical
transmission indeed took place in those affected.,07 In
addition, mothers co-infected with HIV and HCV confer a
risk of up to 50% for vertical transmission of HCV, and
disease progression in these is often more rapid.'OB,lOO
The rate of vertical transmission may be greater in infants
than is shown by seroprevelance studies. Thaler et al."o
found that a high proportion of infants born to HCV-
seropositive mothers were HCV RNA positive despite the
absence of HCV antibodies, and that the disease may
remain silent in many infants. (Seroprevalence studies of
infants also lack specificity as anti-HCV antibodies may be
passively transferred from mother to infant.'O-<
Occupational exposure
Seroprevalence studies of hospital health care workers have
failed to show a significant increase in HCV infection'"
although transmission by needle-stick injury is well
documented in this group"""'''' and transmission may occur
in up to 10% of needle-stick victims. 115 An increased
seroprevelance has been found in dentists, especially those
practising oral surgery and exposed to high-risk patients
such as IV drug users."6.". The relative risk of being HCV
seropositive was 12,9-fold in a study of New York dentists."6
However, there was no increased risk documented in other
studies."9 Military personnel stationed in different






The prevalence varies widely in different geographical
regions and among ethnic groups within regions. Soni et
al. '2' found a seroprevalence of 0,16 - 0,75% in the general
blood donor population of Natal, with the highest prevalence
in the black population (0,75% of blood donors). HCV
antibodies were present in 40% of haemophiliacs and 5% of
dialysis patients but in none of the nurses tested. Because
up to 10% of haemodialysis patients may carry the virus
without developing antibodies122 the true incidence of HCV
infection in renal dialysis patients in this study may have
been as high as 15%. In a population-based study KwaZulu,
1,7% of urban blacks and 0,9% of rural blacks had HCV.'23
An earlier study from South Africa had shown a prevalence
of at least 3,84% in rural and 1,2% in urban blacks,'2'
indicative of a higher prevalence in rural communities. The
prevalence in the latter study may be spuriously high due to
the effect storage of serum has on the first-generation
ELlSAs, which have low specificity. Hepatitis C prevalence
contrasted sharply with that of hepatitis B in all the above
groups suggesting that there may be a different mode of
transmission for the two viruses. The rates in the urban
communities are similar to those in many Western countries.
Prevalence: General
Blood donor-based studies indicate a variable
seroprevalence rate in different countries. Rates in most
Western countries range from 0,3% to 0,7%, but are
0,9 - 1,2% in southern Europe and Japan, with higher
prevalences in southern Italy and eastern Europe. '25
Japanese subjects younger than 20 years have a prevalence
rate of 0,2% but this increases to 4% in subjects older than
50 years. '26,'27 Egypt has one of the highest seroprevalence
rates, up to 22% on ELlSA and 13,6% on RIBA-2 '2• The
very high rate has ben confirmed in numerous studies129"32
and child recipients of blood products have PTH-C infection
rates of up to 55%.'33 The geographical variation in
prevalence may relate to blood transfusion practices before
HCV tests became available in 1989, e.g. the use of paid
donors who have HCV seroprevalence rates of
approximately 10 - 15%134 and the consequent use of
contaminated blood. Other factors include the prevalence of
.IV drug users within a community, variations in HCV
genotype, differences in socio-economic factors and
possibly in previous medical practices. It has been
postulated that the high prevalence in Egypt is due to the
previous multiple re-use of glass syringes for treatment of
schistosomiasis, while in parts of Italy self-injection of
vitamins and tonics may have contributed to HCV spread
(Colombo M. - personal communication).
Post-transfusion hepatitis
The incidence of PTH was 2 - 19% prior to surrogate or
HCV testing of blood donors.'35 Although only approximately
15% of cases of HCV infection can be traced to transfusion
of blood products,'3. HCV currently accounts for more than
82" -100% of cases of PTH worldwide.m ·139 First-
-
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generation (anti-C100-3) tests detected HCV antibodies in
approximately 80% while the second-generation tests were
positive in up to 98% of subjects with PTH."G-'41 PCR also
detected HCV RNA in 4% of patients receiving transfusions
but in whom neither antibodies nor clinical hepatitis
developed; this implied that significant asymptomatic
transmission may occur and that seroprevalence rates may
lack sensitivity. NBNC cases may account for a small
percentage «10%) of PTH patients, but as accuracy of HCV
testing increases, so the NBNC percentage decreases.
These patients tend to have mild disease.
Donor screening has reduced the incidence of PTH
significantly. Use of surrogate markers (ALT and HBcAg) for
hepatitis reduced the incidence of NANB PTH by more than
60% and hepatitis B by 35%.'" In Japan, screening with the
Ortho anti-C 100-3 antibody test reduced the incidence of
PTH in patients receiving 1 - 10 units of blood from 4,9% to
1,9% and in patients receiving 11 - 20 units of blood from
16,2% to 3,3%-''3 Similarly, Donohue et al. ''-4 showed that
the PTH rate dropped from 3,84% in the pre-screening era
to 1,54% with the use of surrogate markers and to 0,57%
with HCV testing.''-4 Currently, the risk of acquiring PTH
increases with the volume of blood transfused and the use
of pooled blood components.
A variety of strategies have been instituted in South Africa
to prevent HCV transmission and are discussed by Bird and
Gibbs on pp 570-572 of this issue. The reduced rate of
PTH may be affected both by screening as well as low
background rates of viral infection in the general population.
Tests which indicate infectivity of blood products must be
specific, in order to reduce discarding of non-infectious
false-positive blood products. Positive surrogate markers
(raised ALT levels) are 60% specific for infectivity of blood
(Le. 40% of blood positive by this test is non-infective), first-
generation assays for antibodies are 70 - 80% specific" and
RIBA-2 is 90% specific.'45 Antibodies do not always indicate
HCV infection, but may represent convalescent antibodies
after recovery form HCV. Therefore, PCR is the most
accurate method to detect HCV RNA and hence infectivity,"·
but is not practical for routine screening. False-negative
antibody tests also occur and, because of current
imprecision of testing, significant numbers of PTH cases
may still occur. It has been estimated that up to 2 000 new
cases could occur annually in the UK. w
Community-acquired (sporadic
hepatitis C
HCV alone does not account for all HAV- and HBV-negative
cases of community-acquired hepatitis with negative
markers. In acute sporadic NANB hepatitis, HCV infection
accounts for only 50 - 82%'''·'50 of cases. Of all HCV
infections, approximately 50% are community acquired
(sporadic) and the rest parenterally acquired. T5O In a
prospective study of NANB hepatitis in 4 sentinal counties in
the USA, 82% of NANB hepatitis cases were due to HCV
infection (Le. 18% NBNC hepatitis). Of the HCV cases, at
least 40% were truly sporadic, in that no parenteral risk
factor could be identified.'5O Chronic hepatitis developed in
62% of all HCV infections and this was similar for both post-
transfusion and sporadic cases. Of the chronic cases, HCV
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RNA persisted in most patients, even those with normal liver





Prior to HCV screening and viral inactivation, 50 - 90% of
haemophiliacs became HCV positive, depending on their
degree of exposure to blood products and the source pf
the blood products.o",oo,T5"'5. The high degree of HCV
contamination of factor VIII is the result of pooling of large
numbers of donor sera in its production. HCV infection in
haemophiliacs is easily missed by serological studies.'58
Seroconversion from an HCV antibody-positive to a negative
state, especially in HIV-positive subjects, may also occur
despite the persistence of HCV RNA in these subjects, many
of whom have ongoing hepatitic inflammation that
progresses to cirrhosis.'57 The situation is further
complicated by the fact that many haemophiliacs do not
develop a significant elevation in serum transaminase levels
or liver disease, despite being HCV positive.'54
The presence of HCV RNA or antibodies in blood
products correlates closely with the probability of these
causing infection in recipients. HCV RNA was detected by
PCR in over 56% of stored clotting factor batches, before
viral screening or inactivation became routine.'''' Viral
inactivation should be by pasteurisationT5• or solvent
detergent inactivation, as heat inactivation alone does not
reduce the infectivity of blood products.''''
Intravenous drug users
Intravenous drug users are an important reservoir for HCV;
45 - 92% are infected. T59·'63 Co-infection with HIV and HBV is
common, although transmission of the different viruses may
occur independently.'·"'&<
Haemodialysis
Approximately 10% of haemodialysis patients in populations
with a low prevalence of HCV,T22,'65,l66 and up to 48% in high-
prevalence areas'·7.,69 are HCV positive, Of these patients,
35 - 75% have abnormal liver tests or histology."o Parenteral
transmission could only be identified in approximately half of
the HCV-positive cases studied, suggesting that dialysis-
associated transmission or increased sporadic transmission
occurs in this group.''','65 Recent work suggests that
nosocomial transmission is probable, as HCV prevalence
was low at initiation of dialysis (4,6%) and increased to 50%
in those on dialysis for> 10 years. Up to 10% of dialysis
patients, including those with active liver disease, may carry
the virus without mounting an antibody response,'" but if
antibodies are positive, the majority of patients will also have
HCV RNA. 171
HCV may reduce antibody responses of HBV
vaccination'" and may cause liver disease in the renal
transplant patient. Previously positive antibodies may
become negative post transplantation because of
immunosuppression, without the patient clearing HCV-RNA.
HCV in transplantation
Approximately half the recipients of HCV-positive organs
may develop liver disease, which may be severe
(subfulminant) in some cases. '73 It is controversial whether
the virus is transmitted by corneal transplantation.'74-175
Acute HCV infection
Clinical features
HCV accounts for the majority of cases (8347 - 100%) of post
transfusion and 20 - 40%47 of the sporadic cases of NANB
hepatitis. 176 The average incubation time is 6 - 12 weeks,177
but may be as short as 14 days if the innoculum is large. 177
However, seroconversion may also be delayed up to 1 year
or indeed may not occur. Antibody titres are lower in those
with acute self-limiting HCV infection, compared with higher
titres in those who have chronic disease.'38 Malaise, fever,
jaundice and dark urine occur in a minority of acute
infections and fewer than 10% of patients become seriously
ill. Hepatitis C rarely causes fulminant liver failure17s-,80 but
may be a co.-factor in causing more severe disease in cases
of acute liver failure (ALF) caused by other agents.'so A
prospective study of 504 cases of PTH C has shown
fulminant hepatitis to be rare and has suggested that
detection of HCV in some studies of fulminant hepatitis was
due to passive transfer of HCV RNA and antibodies to these
patients who had received blood products or exchange
transfusion.'s, Yoshiba et a/.'82 identified 13 patients with
fulminant liver failure and HCV infection and compared them
with HBV fulminant hepatic failure and NBNC ALF. HCV was
associated with less severe but more persistent disease,
several peaks of enzyme rise and a higher mortality rate.
The severity of the acute HCV infection may be affected by
the genotype'83 and acute HCV infection may be caused by
superinfection with a new genotype in a patient with pre-
existing HCV. 184
Diagnosis
Diagnosis of acute HCV infection depends on confirming the
presence of HCV RNA (or antibodies) in patients with acute
PTH or sporadic hepatitis, where other causes have been
excluded. Reverse transcription PCR to detect HCV RNA is
the current gold standard for diagnosing acute HCV
infection,'"",176"s5,'86 but this is a research-based method which
is expensive and requires scrupulous technique. Serological
studies are generally less sensitive, as seroconversion may
only occur weeks, months or years after the onset of clinical
disease.,s7 Anti-C100-3 antibodies, for example, became
detectable only 9 ± 11 weeks after HCV RNA in 25 cases of
acute HCV infections studied by Kato et al. ,'76 and 1 - 80
weeks (mean 11,3 ) in patients studied by McHutchison
et a/.'86 Antibodies to the core protein are often the first
markers to appear after HCV infection and therefore second-
and third-generation assays are more sensitive in detecting
early seroconversion than first-generation assays.'""'"'''''' Core
antigens currently used in detection of specific antibodies
include a 62 Kda fusion protein of HCV core with Maltose-
binding protein's. and a fused chimeric polyprotein of the
immunodominant epitopes of the C (core) and NS3-NS5
(non-structural) proteins.'"' Anticore antibodies were found to
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be predictive of the prognosis in acute HCV infection. If the
disease became chronic, anticore antibodies increased,
whereas they decreased and became undetectable if the
disease resolved." IgM antibody responses to a variety of
recombinant proteins occur in acute HCV infections..• The
most sensitive IgM antibodies were to the nucleocapsid
antigens (core). These became detectable before IgG
antibodies and remained positive for approximately 8
weeks..• Unfortunately, The presence of IgM antibodies do
not always denote acute infection, as these may persist in
chronic disease.
Course and management
As many as 90% of acute HCV infections become chronic"6
and many of these may progress to cirrhosis or
hepatocellular carcinoma. It is unclear whether early
treatment of acute HCV will improve the chances of long-
term cure but several theoretical indications support this
approach. The viral load (as quantified by b-DNA or semi-
quantitative PCR)'90 as well as the number of mutations in
the HCV genome appear to increase progressively with
time.'·' As these factors may be indicators of poor response
to treatment, early treatment may improve the ultimate long-
term cure rate. Pilot studies of interferon a-2a treatment
suggested possible improved cure rates in patients treated
in the acute phase of the disease,'·2 but a controlled trial of
3 months of INF a-2b, 3 million units three times weekly
showed no difference in the prevalence of chronic hepatitis
15 months after cessation of therapy, although
transaminases were significantly improved in the treatment
group after 3 months of therapy.'93 A recent study has shown
a 39% complete recovery rate in patients receiving 3 MU
interferon a-2b for 12 weeks for acute HCV infection, v.
none of the controls.'·4
Chronic hepatitis C infection
Many subjects with positive screening tests have never been
exposed to HCV. The screening tests give false-positive
results in the majority of cases (as expected from Bayes
theorem). Positive tests should therefore be confirmed by
PCR or another supplemental test.
Approximately 60% '52'95,'96 to 90%'26 of patients infected
with HCV develop chronic disease and 50 - 75% have
abnormal transaminase levels at 12 months and chronic
hepatitis on histology.'·7 Although 40% of patients may
experience symptoms at the onset of disease, the majority
subsequently become asymptomatic.'98 Despite the lack of
symptoms, 45 - 62% of HCV-positive blood donors may
have active hepatitis and 7 - 15% cirrhosis.'OO Chronic HCV
infection is usually mild, but is persistent and insidiously
progressive; it rarely remits spontaneously"6 and significant
sequelae occur after prolonged periods, including cirrhosis
and hepatocellular carcinoma. Twenty to 50% of patients
progress to cirrhosis after 10 - 16 years,'·5,'96,200 and
approximately 10% develop end-stage liver failure'95 while
the rest have features of chronic hepatitis. Patients
developing cirrhosis are usually older and anti-HCV antibody
titres are higher in active disease.'98
The spectrum of disease in chronic HCV is variable, and
rapidly progressive cirrhosis may occur, especially in older
-
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patients and those with concomitant HBV'62201.203 or HIV
infection, alcoholic liver disease,"'" or associated
haemochromatosis. The spectrum of disease also includes
carriers with persistently normal serum ALT levels and
minimal-to-mild inflammatory changes in the portal tracts,
associated with low HCV RNA levels.'os It is important to
realise that chronic active hepatitis may be present on
histology, despite the presence of normal ALT.'06
The long-term mortality rate may be slightly increased in
patients with chronic HCV infection. In a case-controlled
study of 568 cases of PTH overall life table analysis of
mortality at 18 years was 51 % for PTH NANB hepatitis, v.
52% and 50% in the two case control groups. There was a
small but significant increase in liver-related mortality (3,3%
v. 1,1 % and 2,0% in case controls P = 0,033) although
alcoholic liver disease was diagnosed in approximately 70%
of these cases.'07 All were cases of post-transfusion hepatitis
and many may have been older subjects with heart disease.
Koretz208 similarly failed to show a significant increased
mortality rate for chronic HCV. This may only be relevant to
older patients and should not be generalised to younger
subjects with HCV. This introduces a bias where competing
causes for death could mask the relative effects of the HCV
and liver disease on mortality. Thus prospective studies of
sporadic and PTH cases need to be performed to allow
estimation of the effects on mortality.
Pathology
Although histological changes are not specific for HCV, they
may help to confirm the diagnosis of HCV hepatitis, to
exclude other or associated causes of liver disease, e.g.
alcoholism, and to document the extent of fibrosis and
cirrhosis; this has therapeutic and prognostic implications.
Histology may not be useful in assessing activity, as disease
activity fluctuates.
The typical changes include piecemeal and spotty
necrosis, acidophilic bodies (apoptotic cells), large droplet
steatosis, Mallory-like bodies, lymphoid aggregates and
follicles (predominantly in the portal regions), bile duct
damage and loss.209 Fibrosis and cirrhosis indicate chronic
disease. While these lesions are characteristic of HCV
hepatitis, they may also be found in other conditions
including auto-immune chronic active hepatitis. The degree
of piecemeal necrosis, fibrosis or cirrhosis, lobular hepatitis,
cellular necrosis and portal inflammation forms the basis of
the description of histology, and terms such as 'chronic
active' of 'chronic persistent' hepatitis are currently not
recommended (Scheuer PT - personal communication).
Relationship of HCV to other
diseases
HCV and hepatocellular carcinoma (HCC)
Many studies have shown an increased prevalence of HCV
markers (HCV RNA and HCV antibodies) in patients with
HCC.,",,103.196.2032,Q.223 The association between HCV and HCC
holds true even in areas of high HBV prevalence'" The
prevalence of HCV infection and its contribution to the
development of HCC varies geographically.211216 Thus
approximately 20% of 128 cases of HCC in South Africa
were positive for RNA or antibodies to HCV on 2nd
generation tests, compared with 94,5% positivity to HBV
markers.''' A meta-analysis of 15 reports of 1 930 patients
with HCC revealed that 47% of the cases were HCV positive
(95% confidence interval 37- 57%), and HBV infection was
present in 59% (95% Cl 27 - 91 %). The odds ratio for
developing HCC in HCV-positive cases was 25 (95% Cl
18 - 33)."· There may be an additive effect in cases of HBV
and HCV co-infection,= which may be indirect and
mediated by cirrhosis.21' Reverse transcription PCR assays
for both positive and negative strand RNA, failed to detect
evidence of HCV infection or replication in the cancerous
tissue, although non-cancerous tissue was positive,220 which
supports an indirect effect of HCV in causing HCC.
HCV and alcoholic liver disease
Patients with alcoholic liver disease have an increased
prevalence of HCV infection. The surprisingly high
prevalence of HCV antibodies in patients with alcoholic liver
disease is not due to false-positive cross reactions;s.
however, interaction between the virus and alcohol is poorly
defined.'04.224'226 HCV was found in 18 - 30% of patients with
alcoholic liver disease.224226 and infected patients developed
liver disease at a significantly younger age than those
without HCV.224.226 Although clinical and pathological grading
were similar in HCV-positive and negative alcoholic patients,
positive patients had higher ALT levels and required
significantly more hospital admissions.226 Rosman et al.'04
found greater degrees of lobular and portal inflammation in
HCV-positive alcoholic patients, but no difference in
perivenular fibrosis or cirrhosis. HCV thus appears to have a
synergistic effect with alcohol in aggravating and
accelerating alcoholic liver disease. It is still unclear why
HCV is so much more common in patients with alcoholic
liver disease.
HCV and prophyria cutanea tarda (PCT)
HCV infection has consistently been found in 62 - 82% of
subjects with sporadic PCT but only in 5% of those with
familial PCT.225,227'230 This strong association may imply that
HCV can trigger or contribute to the development of PCT or
that PCT in some way increases susceptibility to HCV
infection..
HCV and cryoglobulinaemia
Essential mixed cryoglobulinaemia (type 2 cryobulinaemia:
polyclonal IgG and monoclonal IgM rheumatoid factors; type
3: both IgG and rheumatoid factors are polyclonal) manifests
with cutaneous vasculitis, palpable purpura, arthralgias,
neuropathy, and renal and hepatic disease. No cause was
identifiable in most cases, prior to identification of the
hepatitis C virus. Several recent studies have identified HCV
RNA in many of these cases (43 - 84%)231.235 and quantitative
assays indicated that it was concentrated in the
cryoprecipitate with low levels in serum. Antibodies were
only found in 42% of serum samples or cryoprecipitate
suggesting a high false-negative rate for current antibody
tests.''' Clinically the subset of cases with positive HCV
antibodies identified by ELlSA-2 and RIBA-2 had increased
cutaneous involvement, clinical, biochemical and histological
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evidence of more severe liver involvement and lower CH50
complement levels.'32 Of 61 prospectively studied HCV
cases, cryoglobulinaemia was found in 36%, although this
was only clinically manifest in approximately 10%. Seventy
percent of these patients had cirCUlating rheumatoid
factors. 236 Interferon-a may be the therapy of choice for
essential mixed cryoglobulinaemia, in the light of previous
therapeutic trials237 and the presence of HCV in the majority
of cases 23!
HCV and renal disease
Glomerulonephritis with associated proteinuria and
diminished renal and liver function abnormalities,
cryoglobulinaemia, hypocomplementaemia, and
membranoproliferative histology occurs in HCV infection.238
Patients with HCV antibodies and glomerulonephritis all had
HCV RNA in their serum, and circulating immune complexes
and cryoglobulins containing HCV RNA, anti-HCV IgG and
IgM rheumatoid factor to anti-HCV-lgG antibodies.238 Renal
biopsy of these patients showed IgG, IgM and C3
deposition in the glomeruli. Interferon therapy caused
reduced viral replication and was associated with improved
renal and liver functions. The pathogenesis of the
glomerulonephritis is unknown, but it may be due to
glomerular deposition of immune complexes containing
HCV, anti-HCV-lgG, IgM rheumatoid factors and
complement.238
HCV and auto-immune hepatitis
A complex and poorly understood relationship exists
between HCV infection and auto-immune chronic liver
disease (AICLD). The prevalence of HCV antibodies is
increased in patients with AICLD compared with the general
population,216238-2A6 but the association of the virus with auto-
immune liver disease varies geographically."6 Typically, type
2 auto-immune hepatitis,"! which is characterised by
positive liver-kidney microsomal (LKM-1) antibodies and
nonsustained response to steroids, has been associated
with HCV infection, but classic anti-nuclear antibody-
positive type 1 auto-immune hepatitis has also been
associated with this infection.'46 The matter is further
complicated by the demonstration by Yamamoto et al."7 that
the LKM-1 antibodies in anti-HCV positive type 2 AICLD
differed from the LKM-1 antibodies in HCV-negative cases
of type 2 auto-immune hepatitis. In HCV-negative cases,
LKM-1 antibodies recognised a variety of recombinant
synthetic peptides spanning the amino acids between 72
and 456 of the P4502D6 isoform of the P450 microsomal
enzyme. The HCV-positive cases (possibly representing
primary HCV infection with a secondary auto-immune
response) on the other hand reacted with the full length
peptide but not with the smaller peptides.'" However, in
prospectively evaluated cases of HCV chronic active
hepatitis, LKM-1 antibodies were rare, although anti-nuclear
factor and anti-smooth antibodies were found in
approximately 40% of cases.236
Anti-GOR antibodies appear to be uniquely associated
with HCV infection. These antibodies develop to a host-
derived pentadecapeptide in up to 80% of patients with
chronic HCV infection, but less than 10% of patients with
liver disease from other causes.'" The majority of
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responders have HCV RNA, thus anti-GOR antibodies are a
marker for active disease."8.'"9 Antibodies to GOR target
both a host peptide as well as the core antigen of the HCV;
this suggests that these are auto-immune antibodies with
host-viral cross-reactivity.'50
In cases of hepatitis with both HCV and auto-immune
markers, a subgroup behaves like classic auto-immune liver
disease with good steroid responsiveness, whereas others
respond to interferon therapy and behave more like a
primary HCV infection. The presence of jaundice251 found in
76% of cases of AICLD v. 0% of HCV), symptoms251 (97% of
AICLD v. 47% of HCV) and both anti-nuclear and anti-
smooth muscle antibodies239 at presentation are more
suggestive of auto-immune hepatitis in these cases. The
geometric mean titre (1 :160 v. 1:500) of the anti-nuclear
antibodies was lower in cases of HCV liver disease than
AICLD.25! It has also been shown that HCV-derived
antibodies to a host epitope'''3 may develop in the course of
HCV infection; this suggests that the virus may precipitate
auto-immune disease. Auto-antibodies in HCV infection
occur in older patients,25! but their presence does not appear
to affect responsiveness to therapy or to be associated with
an increase in side-effects of treatment. 252 In conclusion,
until the relationship between auto-immune chronic active
hepatitis and HCV infection is better understood, markers
for both diseases should be sought. Therapy, be it interferon
for HCV or steroids for AICLD, should be monitored carefully
and changed if the desired effect is not achieved.
Specifically, patients with AICLD who receive interferon may
deteriorate markedly, while primary HCV infection may be
aggravated by steroids.
Lymphocytic sialadenitis
Lymphocytic sialadenitis or lymphocytic capillaritis and
sialadenitis, which cause xerophthalmia and xerostomia,
were found in 50 - 57% of prospectively evaluated HCV
patients, compared with 5% of controL236.253 The mechanism
of salivary gland involvement in HCV is unknown.'54
HCV and lichen planus (LP)
There is an increased incidence of chronic liver disease in
patients with chronic LP. A recent study found HCV infection
associated with these cases. HCV was diagnosed prior to or
at the same time as LP in the majority.'25 This association
has been confirmed in a controlled study.238
Therapy
Patient selection
Patients with active chronic hepatitis C should be treated
because of the persistent and often progressive nature of
the disease which may lead to hepatocellular carcinoma, or
cirrhosis in 10 - 20% of cases within a decade. Because the
majority of patients with acute HCV remain persistently
infected for many years and may develop cirrhosis, some
authors recommend the treatment of acute HCV infection.'58
The diagnosis of hepatitis C must first be confirmed,
preferably by demonstrating HCV RNA in blood by PCR
-
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(currently only available at selected centres and research
facilities), or by a supplemental test. Disease activity should
also be confirmed by demonstrating raised serum
transaminase values (ALT and AST), abnonmal INR or
albumin levels, and preferably also by showing active
hepatitis on histology. The fluctuant nature of the HCV
activity means that abnormal transaminase values may
occur intermittently, so active disease cannot be excluded
unless several tests performed at 1 - 2 monthly intervals
have been normal. Other causes of hepatitis, e.g. alcoholic
liver disease, auto-immune or HBV hepatitis, which may
require different therapy, should be excluded where
epidemiological or clinical features suggest the possibility of
an alternative or compound diagnosis. Because auto-
immune hepatitis is commonly associated with HCV
infection and may require steroid treatment or be worsened
by interferon therapy, anti-nuclear factor, anti-smooth
muscle antibodies and anti-liver kidney microsomal antibody
levels should be measured prior to initiating treatment.
Specific contraindications to interferon therapy should be
sought, including cirrhosis (as there is very poor
responsiveness and increased risk), auto-immune collagen
vascular disease, psychological depression, bone marrow
insufficiency (especially low white cell count) and active
sepsis. Patients with decompensated cirrhosis may benefit
from low doses of interferon with normalisation of
transaminase values, but therapy has to be given cautiously
in these patients,'57 and closely monitored. Treatment should
not be given until the risk-to-benefit ratio has been carefully
weighed for each individual. Little may be gained in treating
older asymptomatic individuals, as the disease is often more
resistant to therapy in this group, the side-effects of
interferon are greater and the indolent nature of the disease
means that patients are unlikely to develop complications or
symptoms in their normallifespan.
Interferon therapy
Randomised controlled trials of approximately 3 million units
of interferon a-2, three times per week for 6 months, have
shown an approximately 50% apparent clearance of the
virus (usually after 4 - 8 weeks of therapy) and histological
resolution of disease,'58 which lasted until the end of therapy.
Unfortunately there was a 50% relapse rate within 1 - 6
months after cessation of therapy, usually with rises in both
HeV RNA and transaminase values.25S-261 Haemophiliacs had
identical biochemical and histological response and relapse
rates after receiving interferon 3 million units 3 times per
week.,52 They also had a low relapse rate when treated for
1 year.,52 Longer therapy (2: 1 year) has been associated with
an improved cure rate, with an up to 42% sustained
response at 24 weeks follow-up in some,'62,263 but not all,
stUdies.'''' Recurrence of HCV during therapy may be the
result of extensive mutational changes in the virus'65 or the
development of antibodies to interferon.''''
Acute PTH due to HCV responds to interferon therapy, 3
MU three times per week, but responses are not maintained
and no difference in transaminase values was detectable
between treated and untreated groups at 15 months.'93 Trials
are needed for asymptomatic carriers of HCV, as the long-
term natural history of these patients is not well
documented.'66
Predictors of good response to
interferon
The absence of cirrhosis is probably the most important and
consistent predictor of a good response to interferon.'67-270
Other markers of a good response include a short duration
of disease,'7o low gamma glutamyl transferase activity/67,266
lack of obesity, age less than 45 years'69 and the presence of
IgM anti-core antibodies (Which also signals a sustained
response).51.53... Others have not found any biochemical
marker predictive of a good response.'"' A strong predictor
of a good response is the presence of low levels of HCV
RNA at the start of therapy, as measured by semi-
quantitative PCR or b-DNA assays,36.73.27' or HCV antigen
levels in liver biopsy specimens.''' Viral genotypes (which
vary geographically)'73 and the number of strains and
mutations (especially of the hypervariable region of the
envelope E2 gene product) present in an individual may ~i1so
influence the response to therapy. The mutations mClY assist
in escape from immune surveillance.'74 Viral replication in .
peripheral blood mononuclear cells'75 may be associ?ted
with (elapse following cessation of therapy. The response of
HCV to, and host tolerance of, interferon is not significantly
influenced by the presence of HIV infection27.,277 or the
presence of haemophilia. The predictors of response
mentioned above are too inaccurate to be of use in guiding
patient management and it is inappropriate to withhold
therapy on the basis of these predictors.
Alternative forms of therapy
Ribavirin
Ribavirin, a guanosine nucleotide analogue with good oral
bio availability, may improve serum transaminase levels or
reduce HCV RNA levels in approximately 30 - 60% of
patients receiving 600 - 1200 mg/day, but relapses occur in
nearly all patients on withdrawal of this drug.278"83 Its use as
a combination agent with interferon, to improve response
and reduce relapse rates, is currently being studied.
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Hepatitis E
T. J. Tucker, R. E. Kirsch
Hepatitis E, enterically transmitted non-A, non-B hepatitis, is
caused by an RNA virus transmitted via the faecal-oral
route. It usually manifests as an outbreak of waterborne
hepatitis in developing countries where sanitation is poor,
but has also been found to be endemic in these regions.'~
Properties of the hepatitis E
virus
Hepatitis E is a spherical, 27 - 34 nm, non-enveloped single-
stranded RNA virus.3-s On electron microscopy, hepatitis E
virus (HEV) particles have spikes and indentations on their
surfaces. The virus is sensitive to high salt concentrations,
proteolytic digestion and freeze-thawing. The first two
factors probably account for the relatively low numbers of
intact viruses seen in the stools of patients with acute HEV.
HEV has a 7,5 kb, single-stranded, positive-sense RNA
genome. It has three (overlapping) open reading frames
(ORFs), with the non-structural genes located at the 5' end
of the genome and the structural genes at the 3' end.
Although most of the structural proteins are coded within
ORF2, all three frames contribute to the morphology of the
HEV. 3,6
While early studies suggested that HEV was related to the
picornavirus group, its physicochemical properties and
morphology resemble those of the caliciviruses. Subsequent
analysis of the non-structural genes have revealed similarity
to the a-like virus supergroup which includes rubella and the
beet necrotic yellow vein virus.' Final classification of HEV is
pending.
Epidemiology and modes of
spread
HEV has been responsible for several massive outbreaks of
hepatitis, each producing over 10 000 cases. Many of these
outbreaks have occurred as a result of sewage leaking into
river water or a failure of tt)e chlorination process for
drinking water.'" Indeed, hepatitis E is the principal agent for
epidemic hepatitis in developing countries. Outbreaks have
been reported from India, China, Nepal, Bangladesh,
Pakistan and Indonesia.'Q-l< In Africa major outbreaks have
been documented in Algeria,' Ghana" and Ethiopia."
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